Enzalutamide, a second generation androgen receptor antagonist: Development and clinical applications in prostate cancer

Current Oncology Reports

Volumn 15, Issue 2, 2013, Pages 69-75

  Menon, Manoj P ^a   Higano, Celestia S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Abiraterone; Androgen receptor; Antiandrogen; ARN 509; Castration resistant; Enzalutamide; MDV3100; ODM 201; Prostate cancer

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; ANDROSTANOLONE; ANTINEOPLASTIC AGENT; ARN 509; BICALUTAMIDE; CABAZITAXEL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; FLUORO 5 ALPHA DIHYDROTESTOSTERONE; FLUORODEOXYGLUCOSE; HALOPERIDOL; ITRACONAZOLE; MITOXANTRONE; ODM 201; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RADIOISOTOPE; RADIUM 223; RD 162; RU 59603; SIPULEUCEL T; TESTOSTERONE; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD BRAIN BARRIER; BONE METASTASIS; BRAIN LEVEL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG TRANSPORT; DRUG TREATMENT FAILURE; EPILEPTIC STATE; FAINTNESS; FATIGUE; HEART DISEASE; HOT FLUSH; HUMAN; IN VIVO STUDY; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION; METASTASIS POTENTIAL; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; SEIZURE; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; TOXICITY TESTING; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANDROGEN RECEPTOR ANTAGONISTS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 84879601455     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-013-0293-9     Document Type: Article

References (31)

1. Huggins CB, Hodges CV. Studies on prostatic cancer.1. The effect of castration, of estrogen and of androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.
2. American Cancer Society. Cancer facts & figures 2012. Atlanta: American Cancer Society; 2012.
3. Ross RW, Xie W, Regan MM, Pomerantz M, et al. Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer. 2008;112(6):1247-53.
4. Marcelli M, Ittmann M, Mariani S, et al. Androgen receptor mutations in prostate cancer. Cancer Res. 2000;60:944-9.
5. Taplin ME, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med. 1995;332:1393-8.
6. Koivisto P, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57:314-9.
7. Visakorpi T, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 1995;9:401-6.
8. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-9.
9. • Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-54. This study demonstrated that intracrine steroidogenesis maintained intratumoral androgens at levels that could activate AR genes and stimulate tumor growth in CRPC.
10. Berthold DR, Pond GR, Soban F, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26:242.
11. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411.
12. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376:1147.
13. Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2013;13(10):983-92.
14. Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138-48.
15. Fosså SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19(1):62-71.
16. Akaza H, Hinotsu S, Usami M. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115(15):3437-45.
17. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-24.
18. Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis. 1998;1(6):307-14.
19. • Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787-90. This article describes how enzalutamide was designed, reviews the detailed in vitro and in vivo preclinical data, and shows early evidence of clinical efficacy in the first 30 patients who were treated with enzalutamide.
20. • Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437-46. The efficacy data for 140 patients treated with enzalutamide on the phase 1-2 trial are reported in this paper. Significant PSA responses were seen in patients who were treated either before or after receiving chemotherapy. The results of this trial formed the rationale for the two phase 3 trials, AFFIRM (post chemotherapy) and PREVAIL (pre chemotherapy).
21. Higano CS, Beer TM, Yu EY, et al. Antitumor activity of MDV3100 in pre- and post docetaxel advanced prostate cancer: Long-term follow up of the phase 1-2 study. J Clin Oncol. 2011;29 suppl 7 (abstr 1342011).
22. Foster WR, Car BD, Shi H, et al. Drug safety is a barrier to the discovery of new androgen receptor antagonist drugs. Prostate. 2010;71:480-8.
23. • Scher HI, Fizazi K, Saad F, et al. Increased survival with Enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:118-97. The results of the AFFIRM trial, the first of the two phase 3 trials with enzalutamide, are reported in this paper. This trial was conducted in men who had previously been treated with chemotherapy. The results of the phase 3 PREVAIL trial in men with metastatic CRPC who have not yet received chemotherapy have not yet matured at the time of this writing (November 2012).
24. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm317997.htm. Accessed 29 Oct 2012.
25. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203415lbl.pdf. Accessed 30 Nov 2012.
26. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509, a novel antiandrogen for prostate cancer treatment. Cancer Res. 2012;72(6):1-10.
27. Rathkopf D, Antonarakis ES, Shore ND, et al. ARN-509 in men with metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2012;23:ix317. Abstract 984TiP.DE.
28. Smith MR, Antonarakis ES, Ryan CJ, et al. ARN 509 in high-risk patients with non-metastatic castration resistant prostate cancer. Ann Oncol. 2012;23:ix303. Abstract 920P.
29. Massard C, James N, Culine S, Jones R, Vuorela A, Mustonen M, Fizazi K. ARADES trial: a first-in-man, open-label, phaseI/II safety, pharmacokinetic, and proof-of-concept study of ODM-201 in patients with progressive, metastatic castration-resistant prostate cancer. Ann Oncol. 2012;23 Suppl 9. LBA25-PR.
30. Tannock IF, DeWit D, Berry WR, Horti J, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-12.
31. Parker C, Heinrich D, O'Sullivan JM, et al. Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. J Clin Oncol. 2012;30 suppl 5 (abstr 8).